Nine‐Year Trends in Treatment Patterns, Comorbidities, and Healthcare Utilization in Type 2 Diabetes in France: Insights From Integrated Health Data
Clinical and Translational Science · 2026-11 · 19 (11)
DOI: 10.1111/cts.70776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 17.11.2026. Verfasst von Romane Le Goff und 4 weiteren Autor:innen. Beteiligte Einrichtung: Real World Solutions, IQVIA, Paris, France. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Patient Acceptance of Health Care, Hypoglycemic Agents. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes (T2D) is a chronic condition with multimorbidity. Treatment strategies have evolved gradually over the past decades. We described longitudinal treatments, comorbidities, and healthcare resource utilization (HCRU) among adults with T2D in France between 2015 and 2023. The OREOT cohort included adults with T2D identified between 2015 and 2018 in IQVIA Electronic Medical Records and linked to the French National Health Data System. Patients were followed until 31 December 2023. Baseline characteristics, longitudinal clinical data, treatment patterns, incident comorbidities, and HCRU were assessed. Treatment trajectories were reconstructed using state sequence analysis. Among 236,305 patients, 57% were men, and the median age was 67 years. At baseline, 77% of patients had hypertension, 62% had dyslipidemia, and 57% had cardiovascular disease. Over a median follow‐up of 8.7 years, body mass index and HbA1c remained stable, whereas renal markers worsened (mean eGFR −7 mL/min/1.73 m 2 ). Incident comorbidities were frequent, particularly cancer (21%) and chronic kidney disease (11%). Metformin use declined (from 73% to 65%), while use of glucagon‐like peptide‐1 receptor agonists (from 5% to 18%), sodium‐glucose cotransporter‐2 inhibitors (from 0% to 17%), and insulin (from 16% to 22%) increased, alongside growing regimen complexity. Healthcare utilization was characterized by frequent primary care visits (median 49 GP visits), with limited endocrinology (21%) and nephrology (5%) involvement, and regular HbA1c monitoring, with a median of three tests per year. Overall, 20% of patients died during follow‐up. Between 2015 and 2023, T2D management in France shifted toward newer and more complex therapies, while a high burden of comorbidities and progressive renal decline persisted, highlighting the need for coordinated care and long‐term real‐world evaluation of newer glucose‐lowering therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Real World Solutions, IQVIA, Paris, France.
- Department of Medical Pharmacology, Bordeaux University, Bordeaux, France.
ORCID-Profile: Romane Le Goff, Amandine Gouverneur, Pascaline Rabiega, Mathieu Molimard
Zitieren
APA
Le Goff, R., Gouverneur, A., Collin, C., Rabiega, P., & Molimard, M. (2026). Nine‐Year Trends in Treatment Patterns, Comorbidities, and Healthcare Utilization in Type 2 Diabetes in France: Insights From Integrated Health Data. Clinical and Translational Science, 19(11). https://doi.org/10.1111/cts.70776
Vancouver
Le Goff R, Gouverneur A, Collin C, Rabiega P, Molimard M. Nine‐Year Trends in Treatment Patterns, Comorbidities, and Healthcare Utilization in Type 2 Diabetes in France: Insights From Integrated Health Data. Clinical and Translational Science. 2026;19(11). doi:10.1111/cts.70776
BibTeX
@article{LeGoff2026,
author = {Le Goff, Romane and Gouverneur, Amandine and Collin, Cédric and Rabiega, Pascaline and Molimard, Mathieu},
title = {Nine‐Year Trends in Treatment Patterns, Comorbidities, and Healthcare Utilization in Type 2 Diabetes in France: Insights From Integrated Health Data},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {11},
doi = {10.1111/cts.70776}
}
EUVIMED